Company's Profile
Nyrada Inc. is a biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Company’s lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection. The NYR-BI03 has potential to fill a significant treatment gap targeting ischemia-reperfusion injury. NYR-BI03 additionally has the potential to provide dual protection for both the heart and brain from ischemia-reperfusion damage, helping prevent heart failure and neurological damage. Its Neuroprotection Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischaemic stroke. Its Cardioprotection Program is a cardioprotectant drug to reduce the damage to the heart following myocardial infarction (heart attack).
